Gencor Introducing Levagen Branded Palmitoylethanolamide for Joint Health
11.01.18
Ingredient utilizes the endocannabinoid system to support joint function, reduce joint stiffness, and provide joint comfort.
Booth 4773
Gencor, a supplier of clinically researched branded ingredients, will introduce its newest ingredient, Levagen at SupplySide West. Levagen is a branded palmitoylethanolamide (PEA) that has been clinically shown to benefit joint discomfort and support a healthy anti-inflammatory response.
PEA was first identified in the 1950s as a therapeutic substance with potent anti-inflammatory properties. It is produced in the body as a biological response and as a repair mechanism for inflammation. Levagen utilizes the endocannabinoid system for supporting joint function, reducing joint stiffness and providing joint comfort.
“PEA is the first of the next generation anti-inflammatory analgesics,” said Chase Shryoc, vice president of business development at Gencor. “Levagen is a well-researched, self-affirmed GRAS status ingredient with an excellent safety profile. We are thrilled to offer this novel ingredient to U.S. manufacturers.”
As part of this introduction, Gencor is also previewing Levagen+, a cold water dispersible PEA powder specifically designed to increase bioavailability in aqueous environments such as the stomach. With over 90% loading, this formulation supplies the largest amount of PEA in a water dispersible formulation.
“Introducing Levagen+ with LipiSperse technology offers improved functionality and bioavailability of PEA,” said Eric Meppem, co-director at Pharmako Biotechnologies. “LipiSperse is an award-winning delivery system, unlike other technologies currently used in dietary supplements or foods. As a dispersion technology, it has an advantage over SMEDDS technologies, delivering 90% active.”
Gencor, a supplier of clinically researched branded ingredients, will introduce its newest ingredient, Levagen at SupplySide West. Levagen is a branded palmitoylethanolamide (PEA) that has been clinically shown to benefit joint discomfort and support a healthy anti-inflammatory response.
PEA was first identified in the 1950s as a therapeutic substance with potent anti-inflammatory properties. It is produced in the body as a biological response and as a repair mechanism for inflammation. Levagen utilizes the endocannabinoid system for supporting joint function, reducing joint stiffness and providing joint comfort.
“PEA is the first of the next generation anti-inflammatory analgesics,” said Chase Shryoc, vice president of business development at Gencor. “Levagen is a well-researched, self-affirmed GRAS status ingredient with an excellent safety profile. We are thrilled to offer this novel ingredient to U.S. manufacturers.”
As part of this introduction, Gencor is also previewing Levagen+, a cold water dispersible PEA powder specifically designed to increase bioavailability in aqueous environments such as the stomach. With over 90% loading, this formulation supplies the largest amount of PEA in a water dispersible formulation.
“Introducing Levagen+ with LipiSperse technology offers improved functionality and bioavailability of PEA,” said Eric Meppem, co-director at Pharmako Biotechnologies. “LipiSperse is an award-winning delivery system, unlike other technologies currently used in dietary supplements or foods. As a dispersion technology, it has an advantage over SMEDDS technologies, delivering 90% active.”
